Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Total Debt (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Total Debt for 7 consecutive years, with $163.7 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 8.7% to $163.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $163.7 million through Dec 2025, down 8.7% year-over-year, with the annual reading at $163.7 million for FY2025, 8.7% down from the prior year.
  • Total Debt hit $163.7 million in Q4 2025 for Harmony Biosciences Holdings, down from $168.5 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $197.1 million in Q3 2023 to a low of $163.7 million in Q4 2025.
  • Historically, Total Debt has averaged $186.7 million across 5 years, with a median of $191.6 million in 2022.
  • Biggest five-year swings in Total Debt: rose 2.82% in 2023 and later fell 8.7% in 2025.
  • Year by year, Total Debt stood at $192.0 million in 2021, then fell by 0.18% to $191.6 million in 2022, then rose by 1.0% to $193.6 million in 2023, then dropped by 7.39% to $179.3 million in 2024, then fell by 8.7% to $163.7 million in 2025.
  • Business Quant data shows Total Debt for HRMY at $163.7 million in Q4 2025, $168.5 million in Q3 2025, and $172.1 million in Q2 2025.